Navigation Links
More than 600 Risperdal Lawsuit Claims Have Been Filed Alleging Male Breast Growth after Using Antipsychotic Drug
Date:8/9/2014

Columbus, OH (PRWEB) August 09, 2014

Risperdal lawsuits currently pending litigation in the Philadelphia Court of Common Pleas in Pennsylvania have grown to 662 Risperdal lawsuit claims filed against the makers of the antipsychotic drug, notes Wright & Schulte LLC. According to the court documents, the 662 Risperdal lawsuits were filed on behalf of males who allege that they took the antipsychotic drug Risperdal and developed gynecomastia, also known as abnormal male breast growth. Wright & Schulte LLC notes, Risperdal lawsuit claims are also being filed in other courts, including the U.S. District Court, Northern District of California where a complaint alleges a 27-year-old man developed breasts after using Risperdal and underwent a double mastectomy. (3:14-cv-02739) . (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

Wright & Schulte continues to speak with families of young men and adult males who believe they have developed gynecomastia, or enlargement of male breasts, due to taking the antipsychotic drug Risperdal or Risperidone. For a free legal consultation contact the harmful drug attorneys at Wright & Schulte LLC by calling 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information on this ongoing litigation.

Wright and Schulte also notes, that the U.S. Department of Justice (DOJ) reported that in 2013 that Johnson & Johnson’s subsidiary Janssen Pharmaceuticals Inc. plead guilty to misbranding the antipsychotic drug Risperdal and agreed to pay a $400 million criminal fine. This came after an investigation by the DOJ and the FDA for marketing Risperdal without FDA-approval for use in children with behavior challenges, despite Risperdal's known health risks to children and adolescents. According to the DOJ, the FDA repeatedly advised the company that promoting Risperdal's use in children was evidence of a violation of law. Risperdal was not approved for use in children for any purpose until late 2006, according to the Justice Department. Janssen Pharmaceuticals Inc. was also investigated for marketing the Risperdal drug for use in elderly dementia patients that had not been approved by the FDA. As a result of the investigation, the justice department charged Janssen Pharmaceuticals, Inc., with introducing a misbranded drug into interstate commerce. Janssen Pharmaceuticals, Inc. also paid $1.25 billion to settle a separate civil case regarding Risperdal.
[justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013]
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is an atypical antipsychotic drug approved by the U.S. Food & Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. Recent studies have cited concerns over an increase in children being prescribed antipsychotic drugs, including Risperdal. A report released in June by the Australian government’s Drug Utilization Subcommittee estimated 12,680 Australian children less than 19 years old were taking an antipsychotic drug as of October 31, 2012. According to the report, risperidone, sold in the U.S. under the name “risperdal,” was the most common drug taken by children 14 years old and under. In Australia, risperidone is used to treat children and adolescents with behavioral disorders associated with autism, schizophrenia, and bipolar disorder. A study published in the April 2014 issue of Health Day News reviewed data from more than 260,000 children enrolled in one state’s Medicaid program in 2006. According to the report, nearly one-third of children in foster care who had been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) were prescribed antipsychotic drugs, including Abilify, Risperdal and Seroquel, even though the drugs have not been approved by the FDA to treat children with ADHD.
[pbs.gov.au/industry/listing/participants/public-release-docs/antipsychotics/antipsychotics-children-
adolescents.pdf]
[philly.com/philly/health/topics/HealthDay686601_20140410_Too_Many_Foster_Kids_ With_ADHD_Treated_With_Antipsychotic_Drugs__Study.html, HealthDay News, April 10, 2014]

Court records indicated that a Risperdal lawsuit was filed June 12 on behalf of a San Francisco, California man who began taking Risperdal in 2008 when he was 20 years old and continued until 2013. Wright & Schulte learned through court records that the gynecomastia lawsuit purports the San Francisco man developed enlarged breasts, which caused him severe psychological trauma and led him to undergo a double mastectomy in 2011, when he was 24. The lawsuit further purports that the man continued taking Risperdal after the surgery because he did not know that Risperdal allegedly caused the gynecomastia and other side-effects including pain and swelling in his chest, pain in his testicles, testicular shrinkage, loss of sex drive, gastrointestinal problems, anxiety and impaired motor skills. The Risperdal lawsuit accused Johnson & Johnson and Janssen Pharmaceuticals Inc. of misrepresenting the drug as a safe and effective treatment for schizophrenia and bipolar mania even though they knew the drug caused serious side-effects including gynecomastia. The Risperal lawsuit also accused the defendants of failing to adequately warn doctors and consumers about the risk of taking the drug.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Read the full story at http://www.prweb.com/releases/2014/08/prweb12082493.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of New Report Detailing Association Between Risperidone, Development of Gynecomastia in Men
2. Risperdal Lawsuits Mount, With Filing of New Gynecomastia Complaint in New York Federal Court, Bernstein Liebhard LLP Reports
3. Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports
4. Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports
5. New Risperdal Lawsuit Website Published by Bernstein Liebhard LLP; Provides Side Effect Information, Litigation Updates
6. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes New Report Detailing Increasing Use of Risperdal and other Antipsychotic Drugs Among Children
7. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data
8. Risperdal Lawsuits Progress, as Bernstein Liebhard LLP Notes Filing of Plaintiff Brief Seeking to Unseal Risperdal Clinical Studies
9. As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. ... New York, has recently begun offering three new minimally invasive procedures to patients ... procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat ... new videos highlight the importance of correctly using a meat thermometer. The videos ... done extensive research on consumer food safety habits. Dr. Bruhn explains the variety ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit Advisors ... Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, Florida, ... risk while tailoring optimized benefit packages that strengthen the relationship between employer and ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
Breaking Medicine Technology: